CA2737496A1 - Conjugues d'antifolates liant le recepteur de folate - Google Patents
Conjugues d'antifolates liant le recepteur de folate Download PDFInfo
- Publication number
- CA2737496A1 CA2737496A1 CA2737496A CA2737496A CA2737496A1 CA 2737496 A1 CA2737496 A1 CA 2737496A1 CA 2737496 A CA2737496 A CA 2737496A CA 2737496 A CA2737496 A CA 2737496A CA 2737496 A1 CA2737496 A1 CA 2737496A1
- Authority
- CA
- Canada
- Prior art keywords
- conjugate
- antifolate
- linker
- acid
- folate receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9765508P | 2008-09-17 | 2008-09-17 | |
US61/097,655 | 2008-09-17 | ||
PCT/US2009/057363 WO2010033733A1 (fr) | 2008-09-17 | 2009-09-17 | Conjugués d'antifolates liant le récepteur de folate |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2737496A1 true CA2737496A1 (fr) | 2010-03-25 |
Family
ID=42039876
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2737496A Abandoned CA2737496A1 (fr) | 2008-09-17 | 2009-09-17 | Conjugues d'antifolates liant le recepteur de folate |
Country Status (9)
Country | Link |
---|---|
US (5) | US8546425B2 (fr) |
EP (1) | EP2349274A4 (fr) |
JP (1) | JP5675619B2 (fr) |
CN (1) | CN102215844A (fr) |
AU (1) | AU2009293140A1 (fr) |
CA (1) | CA2737496A1 (fr) |
IL (1) | IL211763A (fr) |
NZ (1) | NZ592255A (fr) |
WO (1) | WO2010033733A1 (fr) |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2529758A3 (fr) * | 2003-01-27 | 2013-01-02 | Endocyte, Inc. | Conjugués d'administration de médicaments à liaison au récepteur de vitamines |
EP1789391B1 (fr) | 2004-07-23 | 2017-06-28 | Endocyte, Inc. | Groupes de liaison bivalents et conjugués de ceux-ci |
JP5829793B2 (ja) | 2007-03-14 | 2015-12-09 | エンドサイト・インコーポレイテッドEndocyte, Inc. | 結合性リガンドが結合したツブリシンの薬剤送達結合体 |
US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
JP5690589B2 (ja) | 2007-06-25 | 2015-03-25 | エンドサイト・インコーポレイテッドEndocyte, Inc. | 親水性スペーサーリンカーを含有する結合体 |
US9901567B2 (en) | 2007-08-01 | 2018-02-27 | Syntarga B.V. | Substituted CC-1065 analogs and their conjugates |
AU2008289108C1 (en) | 2007-08-17 | 2024-05-23 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
JP5677970B2 (ja) | 2008-11-03 | 2015-02-25 | シンタルガ・ビーブイ | 新規cc−1065類似体およびその複合体 |
AU2011206133B2 (en) * | 2010-01-12 | 2014-09-18 | Pola Chemical Industries Inc. | Prophylactic or ameliorating agent for pigmentation |
KR20170085143A (ko) | 2010-02-24 | 2017-07-21 | 이뮤노젠 아이엔씨 | 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도 |
US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
LT3056203T (lt) | 2010-04-21 | 2018-03-26 | Syntarga B.V. | Konjugatai cc-1065 analogų ir bifunkcinių linkerių |
CA2812543A1 (fr) * | 2010-09-27 | 2012-04-12 | Endocyte, Inc. | Conjugues de l'acide folique destines a traiter une inflammation de l'oeil |
CN103282777A (zh) * | 2010-11-12 | 2013-09-04 | 恩多塞特公司 | 治疗癌症的方法 |
UA113403C2 (xx) | 2011-04-01 | 2017-01-25 | Спосіб підвищення ефективності folr1 терапії раку | |
TWI597065B (zh) | 2011-06-10 | 2017-09-01 | 梅爾莎納醫療公司 | 蛋白質-聚合物-藥物共軛體 |
WO2013126797A1 (fr) | 2012-02-24 | 2013-08-29 | Purdue Research Foundation | Ciblage du récepteur de la cholécystokinine de type b pour imagerie et thérapie |
EP2822386B1 (fr) * | 2012-02-29 | 2021-05-05 | Purdue Research Foundation | Ligands de liaison au récepteur alpha de folates |
US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
US20140079636A1 (en) * | 2012-04-16 | 2014-03-20 | Dinesh U. Chimmanamada | Targeted therapeutics |
US9884127B2 (en) * | 2012-05-15 | 2018-02-06 | Concortis Biosystems, Corp. | Drug-conjugates, conjugation methods, and uses thereof |
DK3210627T3 (da) | 2012-07-12 | 2023-03-13 | Hangzhou Dac Biotech Co Ltd | Konjugater af cellebindingsmolekyler med cytotoksiske midler |
RS60217B1 (sr) | 2012-08-31 | 2020-06-30 | Immunogen Inc | Dijagnostički testovi i kompleti za detekciju folatnog receptora 1 |
EP2708243A1 (fr) | 2012-09-17 | 2014-03-19 | OntoChem GmbH | Molécules cytotoxiques liés à un ligand de récepteur |
BR112015008365A2 (pt) | 2012-10-16 | 2017-07-04 | Endocyte Inc | composto da fórmula b-l(d)x, ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composição de forma de dosagem unitária ou dose unitária, composição para tratar um câncer em um paciente, e método para tratar um câncer em um paciente |
KR20150104092A (ko) | 2012-11-15 | 2015-09-14 | 엔도사이트, 인코포레이티드 | Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트 |
WO2014080251A1 (fr) | 2012-11-24 | 2014-05-30 | Hangzhou Dac Biotech Co., Ltd. | Lieurs hydrophiles et leurs utilisations pour la conjugaison de médicaments à des molécules se liant aux cellules |
AU2013359506B2 (en) | 2012-12-10 | 2018-05-24 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
EP2931316B1 (fr) | 2012-12-12 | 2019-02-20 | Mersana Therapeutics, Inc. | Conjugués hydroxy-polymère-médicament-protéine |
EP4282419A1 (fr) * | 2012-12-20 | 2023-11-29 | Purdue Research Foundation | Cellules t exprimant un récepteur d'antigène chimérique et produits thérapeutiques anticancéreux |
CA2903994C (fr) | 2013-03-15 | 2017-08-22 | Philip S. Low | Synthese et composition de groupes de liaison d'acides amines conjugues a des composes utilises pour l'imagerie ciblee de tumeurs |
HUE055856T2 (hu) | 2013-08-30 | 2021-12-28 | Immunogen Inc | Antitestek és vizsgálatok a folsavreceptor 1 kimutatására |
AU2014318826B2 (en) | 2013-09-10 | 2019-10-10 | Madrigal Pharmaceuticals, Inc. | Targeted therapeutics |
EP3415489A1 (fr) | 2013-10-18 | 2018-12-19 | Deutsches Krebsforschungszentrum | Inhibiteurs marqués de l'antigène membranaire spécifique de la prostate (psma), leur utilisation comme agents d'imagerie et agents pharmaceutiques pour le traitement du cancer de la prostate |
WO2015066053A2 (fr) | 2013-10-28 | 2015-05-07 | Synta Pharmaceuticals Corp. | Thérapies ciblées |
EP3074773A1 (fr) | 2013-11-25 | 2016-10-05 | OntoChem GmbH | Procédé pour diagnostic de maladies associées à un récepteur couplé aux protéines g |
LT3092010T (lt) | 2014-01-10 | 2018-10-25 | Synthon Biopharmaceuticals B.V. | Metodas, skirtas gryninimui cys-sujungtų antikūno-vaisto konjugatų |
JP6224268B2 (ja) | 2014-01-10 | 2017-11-01 | シントン・バイオファーマシューティカルズ・ビー.ブイ.Synthon Biopharmaceuticals B.V. | 子宮内膜癌の治療において使用するためのデュオカルマイシンadc |
KR102344354B1 (ko) | 2014-01-10 | 2021-12-28 | 비온디스 비.브이. | 향상된 생체내 항종양 활성을 나타내는 듀오카르마이신 adc |
WO2015116774A1 (fr) | 2014-01-29 | 2015-08-06 | Synta Pharmaceuticals Corp. | Agents thérapeutiques cibles |
FI3122757T3 (fi) | 2014-02-28 | 2023-10-10 | Hangzhou Dac Biotech Co Ltd | Varautuneita linkkereitä ja niiden konjugointikäyttötapoja |
WO2015134464A2 (fr) | 2014-03-03 | 2015-09-11 | Synta Pharmaceuticals Corp. | Thérapies ciblées |
WO2015135659A1 (fr) | 2014-03-14 | 2015-09-17 | Ontochem Gmbh | Ligand-récepteur lié à des molécules cytotoxiques |
EP3131586A4 (fr) | 2014-03-18 | 2017-10-25 | Madrigal Pharmaceuticals, Inc. | Agents thérapeutiques cibles |
US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
US9481678B2 (en) * | 2015-02-09 | 2016-11-01 | Duquesne University Of The Holy Ghost | Substituted pyrrolo[2,3-D]dipyrimidines for selectively targeting tumor cells with FR-alpha and FR-beta type receptors |
EP3268046A4 (fr) | 2015-03-13 | 2018-11-21 | Endocyte, Inc. | Conjugués pour le traitement de maladies |
US20180110871A1 (en) * | 2015-04-17 | 2018-04-26 | Endocyte, Inc. | Dual disulfide drug conjugates |
JP6772186B2 (ja) * | 2015-05-01 | 2020-10-21 | エンドサイト・インコーポレイテッドEndocyte, Inc. | 炎症の治療のための抗葉酸剤結合体 |
US10406238B2 (en) | 2015-05-11 | 2019-09-10 | Purdue Research Foundation | Ligand ionophore conjugates |
EP3319936A4 (fr) | 2015-07-12 | 2019-02-06 | Suzhou M-conj Biotech Co., Ltd. | Lieux de pontage pour la conjugaison des molécules de liaison cellulaire |
US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
IL257531B2 (en) | 2015-09-17 | 2023-04-01 | Immunogen Inc | Medicinal compositions containing anti-folr1 immunoconjugates |
US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
MX2018006218A (es) | 2015-12-04 | 2018-09-05 | Seattle Genetics Inc | Conjugados de compuestos de tubulisina cuaternizada. |
EP3600430A4 (fr) * | 2016-03-29 | 2020-12-30 | Endocyte, Inc. | Conjugué de folate destiné à être utilisé dans le ciblage de macrophages associés à une tumeur |
WO2017205447A1 (fr) * | 2016-05-24 | 2017-11-30 | Endocyte, Inc. | Méthodes de traitement du cancer avec un composé ligand de psma-tubulysine |
US10239891B2 (en) * | 2017-05-15 | 2019-03-26 | Indicator Systems International, Inc. | Compositions to detect remnant cancer cells |
WO2018026965A1 (fr) | 2016-08-02 | 2018-02-08 | Isi Life Sciences, Inc. | Méthode de détection de cellules cancéreuses. |
US20180036312A1 (en) * | 2016-08-02 | 2018-02-08 | ISI Life Sciences Inc. | Novel Scaffolds for Intracellular Compound Delivery for the Detection of Cancer Cells |
NZ752394A (en) | 2016-11-14 | 2021-07-30 | Hangzhou Dac Biotech Co Ltd | Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers |
AU2018219226A1 (en) | 2017-02-07 | 2019-08-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
JP7178355B2 (ja) | 2017-02-28 | 2022-11-25 | エンドサイト・インコーポレイテッド | Car t細胞療法のための組成物および方法 |
US10753942B2 (en) | 2017-05-15 | 2020-08-25 | Indicator Systems International, Inc. | Methods to detect remnant cancer cells |
IL299893A (en) | 2017-06-20 | 2023-03-01 | Madrigal Pharmaceuticals Inc | prescribed medications |
JP2020524156A (ja) | 2017-06-20 | 2020-08-13 | マドリガル ファーマシューティカルズ インコーポレイテッドMadrigal Pharmaceuticals,Inc. | 標的治療薬を含む併用療法 |
EP3743082A4 (fr) | 2018-01-22 | 2021-11-03 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | Procédés d'utilisation de cellules t car |
SG11202106209RA (en) | 2018-12-19 | 2021-07-29 | Univ Leland Stanford Junior | Bifunctional molecules for lysosomal targeting and related compositions and methods |
BR112021025984A2 (pt) | 2019-06-29 | 2022-04-12 | Hangzhou Dac Biotech Co Ltd | Conjugado de anticorpo-derivado de tubulisina b (análogo), composto, composição farmacêutica, e, usos do conjugado, dos compostos e das composições farmacêuticas |
JP7489472B2 (ja) | 2020-10-27 | 2024-05-23 | エルシダ オンコロジー, インコーポレイテッド | ナノ粒子を官能化する方法 |
JP2023554517A (ja) * | 2020-12-22 | 2023-12-27 | エフ. ホフマン-ラ ロシュ アーゲー | 試料中の目的の分析物を検出するための方法 |
TW202339803A (zh) * | 2021-11-09 | 2023-10-16 | 德商圖布里斯有限公司 | 包含磷(v)及喜樹鹼分子部分的共軛物 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4024A (en) * | 1845-05-01 | Cutting and crushing corn-fodder | ||
US4713249A (en) | 1981-11-12 | 1987-12-15 | Schroeder Ulf | Crystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereof |
US5266333A (en) | 1985-03-06 | 1993-11-30 | American Cyanamid Company | Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone |
ZA861235B (en) * | 1985-03-08 | 1986-10-29 | Univ Princeton | Pyrido(2,3-d)pyrimidine derivatives |
US5417982A (en) | 1994-02-17 | 1995-05-23 | Modi; Pankaj | Controlled release of drugs or hormones in biodegradable polymer microspheres |
US5547668A (en) | 1995-05-05 | 1996-08-20 | The Board Of Trustees Of The University Of Illinois | Conjugates of folate anti-effector cell antibodies |
AUPQ014799A0 (en) * | 1999-05-04 | 1999-05-27 | Access Pharmaceuticals Australia Pty Limited | Amplification of folate-mediated targeting to tumor cells using polymers |
DE60231868D1 (de) | 2001-04-24 | 2009-05-20 | Purdue Research Foundation | Folat-mimetika und deren folatrezeptorbindende konjugate |
EP2529758A3 (fr) | 2003-01-27 | 2013-01-02 | Endocyte, Inc. | Conjugués d'administration de médicaments à liaison au récepteur de vitamines |
FR2856689A1 (fr) * | 2003-06-25 | 2004-12-31 | Guerbet Sa | Composes specifiques a forte relaxivite |
US7290958B2 (en) | 2004-12-03 | 2007-11-06 | Airfield Systems, Llc | Subsurface drainage system and drain structure therefor |
WO2006101845A2 (fr) | 2005-03-16 | 2006-09-28 | Endocyte, Inc. | Synthese et purification d'acide pteroique et des conjugues de celui-ci |
US20080280937A1 (en) | 2005-08-19 | 2008-11-13 | Christopher Paul Leamon | Ligand Conjugates of Vinca Alkaloids, Analogs, and Derivatives |
JP5475992B2 (ja) | 2005-08-19 | 2014-04-16 | エンドサイト,インコーポレイテッド | 多剤リガンド結合体 |
CA2619992A1 (fr) * | 2005-08-24 | 2007-03-01 | Protherics Medicines Development Limited | Clivage de composes antifoliques |
JP5690589B2 (ja) | 2007-06-25 | 2015-03-25 | エンドサイト・インコーポレイテッドEndocyte, Inc. | 親水性スペーサーリンカーを含有する結合体 |
-
2009
- 2009-09-17 US US13/063,889 patent/US8546425B2/en active Active - Reinstated
- 2009-09-17 AU AU2009293140A patent/AU2009293140A1/en not_active Abandoned
- 2009-09-17 CN CN2009801425326A patent/CN102215844A/zh active Pending
- 2009-09-17 CA CA2737496A patent/CA2737496A1/fr not_active Abandoned
- 2009-09-17 WO PCT/US2009/057363 patent/WO2010033733A1/fr active Application Filing
- 2009-09-17 EP EP09815218.4A patent/EP2349274A4/fr active Pending
- 2009-09-17 NZ NZ592255A patent/NZ592255A/xx not_active IP Right Cessation
- 2009-09-17 JP JP2011527074A patent/JP5675619B2/ja active Active
-
2011
- 2011-03-16 IL IL211763A patent/IL211763A/en not_active IP Right Cessation
-
2013
- 2013-08-26 US US14/010,122 patent/US9192682B2/en active Active
-
2015
- 2015-10-21 US US14/919,518 patent/US9549992B2/en active Active
-
2016
- 2016-12-13 US US15/377,844 patent/US10363250B2/en active Active
-
2019
- 2019-06-13 US US16/440,882 patent/US11219622B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN102215844A (zh) | 2011-10-12 |
US11219622B2 (en) | 2022-01-11 |
EP2349274A4 (fr) | 2014-12-17 |
AU2009293140A1 (en) | 2010-03-25 |
US20170246314A1 (en) | 2017-08-31 |
US20140213760A1 (en) | 2014-07-31 |
US10363250B2 (en) | 2019-07-30 |
US8546425B2 (en) | 2013-10-01 |
US9549992B2 (en) | 2017-01-24 |
IL211763A0 (en) | 2011-06-30 |
JP2012502921A (ja) | 2012-02-02 |
US9192682B2 (en) | 2015-11-24 |
US20200147072A1 (en) | 2020-05-14 |
NZ592255A (en) | 2013-07-26 |
JP5675619B2 (ja) | 2015-02-25 |
WO2010033733A1 (fr) | 2010-03-25 |
US20160263237A1 (en) | 2016-09-15 |
WO2010033733A4 (fr) | 2010-05-06 |
US20110172254A1 (en) | 2011-07-14 |
EP2349274A1 (fr) | 2011-08-03 |
IL211763A (en) | 2014-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11219622B2 (en) | Folate receptor binding conjugates of antifolates | |
US10738086B2 (en) | Conjugates containing hydrophilic spacer linkers | |
US20170327537A1 (en) | Binding ligand linked drug delivery conjugates of tubulysins | |
AU2004210136B2 (en) | Vitamin receptor binding drug delivery conjugates | |
US20130116195A1 (en) | Binding ligand linked drug delivery conjugates of tubulysins | |
EP2374480A2 (fr) | Conjugués de ligands multi-médicaments | |
US10500204B2 (en) | Vitamin receptor drug delivery conjugates for treating inflammation | |
US20130203680A1 (en) | Folate conjugates for treating inflammation of the eye | |
AU2013203147A1 (en) | Binding ligand linked drug delivery conjugates of tubulysins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20140731 |
|
FZDE | Discontinued |
Effective date: 20161031 |